| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Andrology and IVF Laboratories, Departments of Surgery (Urology), Obstetrics and Gynecology, and Physiology, University of Utah School of Medicine, Salt Lake City, Utah.
| Correspondence to: Dr Douglas T. Carrell, Andrology and IVF Laboratories, 675 S. Arapeen Dr, Suite 205, Salt Lake City, UT 84108 (e-mail: douglas.carrell{at}hsc.utah.edu). |
Severe male infertility has been shown to be associated with improper
meiotic recombination and elevated sperm chromosome aneuploidy. Elevated sperm
aneuploidy increases the risk of embryo lethality or fetal anomalies. Although
difficulties in interpreting aneuploidy data still exist, advances in
fluorescent in situ hybridization (FISH) technology have facilitated the study
of sperm from patients with severe spermatogenesis defects, which has
demonstrated the prudence of evaluating sperm chromosome aneuploidy in men
with severe male factor infertility, such as nonobstructive azoospermia or
severe ultrastructure defects, especially in cases of previous repeated in
vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) failure.
Testing is also advisable in men with chromosome translocations and
unexplained recurrent pregnancy loss, and it may be beneficial in patients
with unexplained, repeated IVF failure. Automated FISH imaging and analysis
technology is now available and is beneficial in reducing technician time
analyzing sperm aneuploidy. Emerging technologies, such comparative genomic
hybridization, may be beneficial in further improving the quality of data
derived from aneuploidy analysis and reducing the cost of the assay.
Key words: FISH, meiotic recombination, chromatin
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |